Albany, NY -- (SBWIRE) -- 04/30/2014 -- The report entitled "Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis" published in January 2014 is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs.
Click Here to Read Complete Report @ http://www.researchmoz.us/antibody-drug-conjugates-2014-a-business-technology-and-pipeline-analysis-report.html.
The commercial value of ADC technologies, ADC products and ADC product candidates is described and valued by means of sales, product prices, company market capitalization, initial public offerings, venture capital and private equity financing, infrastructure investments and financial deal terms. Business deal activities in form of acquisitions, licensing and collaboration agreements and joint ventures between pharma, biotech and the service industry serve to identify those technologies of interest for stakeholders in the ADC industry.
Download Sample Pages: Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis
The report was built from the bottom-up by first elaborating Company Profiles from information retrieved from La Merie‘ proprietary antibody-drug conjugate database, scientific literature and abstracts, company press releases, company presentations, financial disclosures, clinical trials databases and company websites. A structured analysis was performed for the ADC pipeline, for stakeholders of the ADC industry, for state-of-the art and emerging ADC technologies, for the ADC manufacturing and service industry, and business activities. The report identifies trends for those ADC technologies (target, antibody, drug, linker and conjugation systems) which are of interest for the industry.
Browse All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html.
The report includes in the Addendum a tabulated Competitor Analysis and lists all relevant business transactions of the last two to three years.
Spefically, the ADC pipeline analysis describes preclinical, non-clinical and clinical ADC projects and R&D programs. It evaluates the ADC targets in relation to drug and linker systems, and also investigates the clinical success and reasons for failures of antibody-drug conjugates.
The stakeholder analysis compares companies with their peers in the respective group of development, technology and manufacturing companies and further categorizes them within the respective group to find out their competitive situation.
The analysis pays special attention to the importance of target selection, to emerging trends of new targeting moieties beyond full-length, canonical antibodies, to the expansion of the use of ADCs in non-cancer indications, to the opportunities arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs.
All Countrywise Report @ http://www.researchmoz.us/country.html.
Crticial issues of ADCs, such as therapeutic window, druggable targets, manufacturing and financing are addressed and opportunities outlined.
List of Tables
Table 1 Overall pipeline of Antibody-Drug Conjugates and Immunoconjugates
Table 2: Targeting moieties used in ADCs and Immunoconjugates
Table 3: Drugs used in ADCs
Table 4: Other and novel payloads used in ADCs and Immunoconjugates
Table 5: Stable and cleavable linkers for ADCs with auristatins or maytansinoids
Cancer Treatment Drugs Markets in China
China's demand (http://www.researchmoz.us/cancer-treatment-drugs-markets-in-china-12-full-research-reports-collection-report.html) for cancer treatment drugs markets has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This is a collection of 12 full market research reports on lung cancer, breast cancer, prostate cancer, leukemia, ovrian cancer, colon cancer, cevical cancer, brain cancer, bladder cancer, liver cancer, kidney cancer, and skin cancer treatment drugs. These new studies examine China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021 are presented. Major producers in China are profiled.
Common Disease Treatment Drugs Markets in China
China's demand (http://www.researchmoz.us/common-disease-treatment-drugs-markets-in-china-13-full-research-reports-collection-report.html) for common disease treatment drugs markets has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This is a collection of 13 full market research reports on cardiovascular, allergy, arthritis, asthma, diabetes, hepatitis, pain and fever relief, cough, cold and flu, infectious disease, respiratory, tuberculosis, and digestive remedies. These new studies examine China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021 are presented. Major producers in China are profiled.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis.We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports.We provide our services to all sizes of organizations and across all industry verticals and markets.Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Browse Blog - http://pramoddige91.wordpress.com/